The role of endogenous Y 1 -receptor activation on skeletal muscle vasculature under baseline conditions is currently debated and no in vivo studies have been performed to address this issue. Therefore, this study was designed to address the effect of Y 1 -receptor and/or 1 -adrenoceptor antagonism on basal hindlimb vascular conductance in male Sprague-Dawley rats in vivo. Left hindlimb vascular conductance, carotid artery mean arterial pressure, and heart rate were measured during low volume infusion of BIBP3226 (100 µg/kg), prazosin (20 µg/kg), and combined blockade to the left hindlimb. Vascular conductance increased 1.5 ± 0.5 µl/min/mmHg with BIBP3226 infusion, 1.7 ± 0.5 µl/min/mmHg with prazosin infusion, and 4.8 ± 1.0 µl/min/mmHg with combined blockade (P < 0.05). Interestingly, systolic vascular conductance increased in all 3 conditions, but diastolic vascular conductance only increased in the two conditions where BIBP3226 was present. These data indicate that Y 1 -receptor activation plays an important role in the regulation of vascular conductance in the resting rat hindlimb. Furthermore, this effect was of the same magnitude as the 1 -adrenoceptor contribution. The differential flow profiles following 1 blockade with and without Y 1 -receptor blockade supports local differences in receptor distribution.
Introduction
The sympathetic branch of the autonomic nervous system is an essential modulator of the peripheral circulation and blood pressure. Several reports indicate an association between essential hypertension and augmented sympathetic nerve activity and its link to the increase in vascular resistance (19) and wall thickness (7). These combined effects of sympathetic outflow appear to include the dual actions of the sympathetic neurotransmitters norepinephrine (NE) and neuropeptide Y (NPY) acting on postjunctional and Y receptors, respectively.
Neuropeptide Y (NPY), a 36 amino acid residue is co-stored with norepinephrine (NE) within peripheral sympathetic nerves that supply blood vessels. Nerve fibers that contain NPY are more abundant around resistance vessels and become denser with decreasing vessel size (35) . It has been established that the receptor responsible for NPY's vasoconstrictor effects in cat skeletal muscle is the NPY-Y1-receptor (9). NPY has been implicated in hypertension (22) with high circulating levels in both men and women with the disease (38) . Moreover, the mitogenic potential of NPY has been established (29; 34; 40; 41) . Nonetheless, it is reasonable to expect that Y 1 -receptor activation must occur chronically under baseline conditions if it is to factor importantly in long-term blood pressure regulation, and/or mitogenic effects. However, chronic basal Y 1 -receptor activation has not been demonstrated with certainty.
The relationship between basal Y 1 -receptor activation and blood pressure regulation is debated. Evidence from Y 1 -receptor knockout mice that display normal basal blood pressure (26) suggests that NPY does not play a critical role in blood pressure maintenance. Moreover, infusion of the Y 1 -receptor antagonist BIBP3226 does not affect basal blood pressure in normotensive and spontaneously hypertensive rats (which have elevated plasma NPY levels) (39) . Consequently, interest in the role of NPY as a regulator of baseline blood pressure has declined whereas, its role during shock and/or chronic stress (e.g., sepsis, hemorrhage, cold stress) has been expressed (30; 43) . This evidence has contributed to the concept that the release of NE and NPY is differentially regulated (1; 3; 17) with NE released at lower nerve activity and NPY released only under high neuronal stimulation frequencies. In this model it is proposed that NE is contained and released from small dense cored vesicles (SDCV) whereas NPY is contained within large dense cored vesicles (LDCV). This hypothesis predicts that NE primarily controls vascular smooth muscle tone during basal conditions whereas NPY should not, its release only occurring during periods of high stress. Pharmacological and physiological studies support the differential release of NPY and NE (16; 17) .
However, data from a series of studies by De Potter et al. bring into question differential release of NE and NPY (4) (5) (6) ) . This group has tested a number of different vascular beds innervated by sympathetic nerves with differing ratios of LDCV and SDCV including the isolated perfused sheep spleen, dog spleen, and rat vas deferens (the latter containing primarily SDCV) (4; 5). They have reported that at nerve stimulation frequencies ranging from 2 to 20 Hz, the ratio of NE to NPY remains constant (5) . From this perspective both NPY and NE should contribute to baseline vascular tone.
Thus, the aim of the present study was to test the hypothesis that Y 1 -receptor activation contributes importantly to baseline vascular tone. This hypothesis was addressed by examining the effect of selective Y 1 -receptor and/or 1 -adrenoceptor antagonism on basal hindlimb vascular conductance in male Sprague-Dawley rats in vivo.
In the current study, skeletal muscle vasculature was investigated because it has a high level of basal tone and a large range of response to changes in physiological state that contribute to blood pressure control both at rest and during stress. The results indicate that Y 1 -receptor activation contributes importantly to baseline hindlimb vascular tone.
Methods
The Council on Animal Care at the University of Western Ontario approved the experimental protocol.
Animals
Twenty-three adult male Charles River Sprague-Dawley rats (body weight 256-426g; Charles River Laboratories, Wilmington, MA) were used in this study. Rats were housed in a temperature (24 ºC) and light (12 hour cycle) controlled room in standard plexiglass cages, fed rat chow (Prolab Rat, Mouse and Hamster 3000 Diet) and were allowed to eat and drink water ad libitum. Prior to surgery animals were anesthetized with an intraperitoneal injection of thiobutabarbital sodium (Inactin; 100 mg/kg; SigmaAldrich). Internal body (rectal) temperature was monitored continuously and was maintained at 37 0.5 ºC using a thermally controlled water-perfused heating pad.
Surgery
A tracheal cannula was inserted to facilitate spontaneous respiration, and end-tidal CO 2 (ET CO2 ) measures were made from expired air at periods throughout the experiment.
The left common carotid artery was cannulated with polyethylene tubing (PE50) to permit arterial blood pressure (ABP) recording from the amplified signal (ML118 Powerlab Quad Bridge Amplifier; ADInstruments, Colorado Springs, CO) of a pressure transducer (MLT844; ADInstruments, Colorado Springs, CO).
Through a midline abdominal incision, the gut was carefully moved aside and covered with sterile gauze moistened with sterile saline (0.9% NaCl). Using cotton swabs a small portion of the descending aorta and right iliac artery were cleaned of fat and exposed. The right iliac artery was cannulated (PE50) and the tubing was advanced to the bifurcation of the aorta. This cannula was used for drug delivery to the left hindlimb, such that perfusion of drug was directed into the flow of blood traveling from the descending aorta to the left hindlimb. Immediately following these procedures, the gauze was removed and contents of the gut were repositioned. The neck and abdominal incisions were stapled immediately following the surgery (Becton-Dixon, 9mm stainless steel wound clips).
Femoral artery blood flow (Q fem ) was measured using a Transonic flowmeter (TS420 Perivascular Flowmeter Module; Transonic Systems Inc., Ithaca NY) and Transonic flowprobe (0.7PSB) positioned approximately 3mm distal to the femoral triangle. Special care was taken to ensure that surrounding nerves and vessels were not damaged during this procedure. Innocuous water-soluble gel was spread over the entire opened area of the hindlimb to maintain hydration of exposed tissue and quality of arterial flow signal.
Experimental protocol
Animals recovered for 1 hour following surgery; however BP and HR were stable and at normal levels within 30 minutes. After recovery, a vehicle (0.9% saline) infusion (160 µl) was carried out followed by 10 minutes recovery. Baseline data were recorded for five minutes followed by one of three bolus drug infusions (carried out on 3 separate (not presented) confirmed that 100 µg/kg BIBP3226 provided the maximal dilator response in this preparation. Our preliminary data also established that 20 µg/kg prazosin caused the least systemic effect (i.e., drop in BP) for the greatest increase in hindlimb blood flow. Furthermore, it was confirmed that the drug doses utilized completely blocked the Y 1 -and 1 -receptors in our model. Specifically, the agonist-induced decrease in vascular conductance (60 ± 13 % with 100 nM NPY and 49 ± 6 % with 3 µM NE; n=3 animals) was completely abolished by a subsequent dose of the respective antagonist (100 µg/kg BIBP3226 or 20 µg/kg prazosin). Moreover after receptor blockade, an ensuing infusion of the corresponding agonist (either 100 nM NPY or 3 µM NE) had no effect on hindlimb vascular conductance.
Data Analysis
All data were collected online using a Powerlab data acquisition system (ADInstruments, Colorado Springs, CO). Heart rate (HR) and mean arterial pressure (MAP) were calculated from the ABP signal. Vascular conductance was calculated as the ratio of Q fem /MAP. For all conditions, Q fem , hindlimb (systolic, diastolic, and mean) vascular conductance, MAP, and HR were calculated as a 5 minute stable average during the baseline period (BASELINE) and as a 1 minute average at the peak of the drug response (DRUG). To test for intra-condition differences between BASELINE and DRUG paired t-tests (2 tailed) were used. Inter-condition differences in the aforementioned variables were assessed using one-way analysis of variance (ANOVA).
In the event of statistical significance (P<0.05) a post-hoc Tukey test was used to identify conditions that differed. Data are presented as mean (±SE).
Results
Animals exhibited normal MAP (103 to 106 mmHg) and HR (328 to 351 bpm) levels during the baseline period and there were no inter-condition differences among these variables (Table I) . Furthermore, end tidal CO 2 in all conditions remained in the normal range throughout the experiment (38 to 42 mmHg). Vehicle infusion did not affect any of the measured variables in any of the conditions. Baseline vascular conductance levels for the various groups were not different prior to any of the pharmacological treatments ( Table 2) .
Effect of Y 1 -receptor antagonism (BIBP3226; n=7)
MAP and HR were unaffected by BIBP3226 infusion (Table I) 
Effect of 1 -receptor antagonism (prazosin; n=8)
MAP decreased with prazosin infusion from 103 ± 3 to 87 ± 3 mmHg and HR was unaffected (Table I) 
Effect of combined Y 1 -and 1 -receptor antagonism (BIBP3226 +prazosin; n=8)
MAP decreased from 106 ± 3 to 85 ± 4 mmHg (P<0.05) and HR was unaffected by combined Y 1 -and 1 -receptor antagonism (see Table I Infusion of combined BIBP3226 + prazosin resulted in an increase in diastolic blood flow and diastolic vascular conductance above baseline (218 ± 79 µl/min and 2.4 ± 0.9 µl/min/mmHg respectively). This increase was similar to that observed in the BIBP3226 condition but was different from the prazosin condition (Figure 2 ; P<0.05).
Discussion
The primary and novel observation from this study was the increase in baseline hindlimb blood flow and vascular conductance following Y 1 -receptor blockade. An unexpected observation of the current study was that the increase in mean vascular conductance was similar following BIBP3226 or prazosin treatment, but this was achieved by different flow response profiles in the two conditions. There was an increase in systolic conductance from baseline in both treatments. However, diastolic conductance increased following the BIBP3226 treatment but not following prazosin.
Furthermore, diastolic and systolic conductance increased when both drugs were given simultaneously. This pattern may be explained by the differential distribution of 1 -adrenoceptors and Y 1 -receptors. Both in vitro (11) and in vivo (9; 15) studies have shown that NPY promotes only a weak constriction in large blood vessels and the preferential site of action occurs on the small arterioles (< 25 m). Additionally, intravital microscopy studies demonstrate that adrenergic regulation of large arterioles and venules in skeletal muscle involves both 1 -and 2 -adrenoceptors with higher concentrations of BIBP3226 alone); however, sample size calculations indicated that at least 32 animals would be required to observe such an effect. Overall, it is proposed that more specific experimental designs will be required to address whether differential distribution of Y 1 versus 1 -receptors minimize the potential for interactive post-receptor effects in skeletal muscle vessels.
In the present study there was no heart rate response with prazosin-induced hypotension, an observation that is consistent with previous examinations (18; 20; 25) .
Assuming normal baroreflex control a significant drop in blood pressure should elicit reflex tachycardia. The explanation for this contradictory response likely relates to the impact of prazosin on intracellular levels of cyclic GMP at cholinergic receptor sites in the heart (13).
A potential limitation of this study is that barbiturate anesthetics may increase the systemic adrenergic activity (36) . Such an effect might cause an overestimation of normal NPY effects on baseline vascular tone. However, studies in awake and anesthetized animals suggest that this class of anesthetics (including Inactin; sodium thiobutabarbital) has little affect on basal organ vascular conductance (2). Furthermore, Matsukawa and Ninomiya (21) observed that sympathetic levels did not vary between the first and fourth hour after barbiturate (pentobarbital) anesthesia and that these levels were not different from awake rest levels. Our experiments commenced one hour post-surgery and were completed (including surgical time) before the four-hour limit observed in this previous study (21) . Additionally, Matsukawa and Ninomiya confirmed that the relative increase in sympathetic outflow after four hours of anesthesia was related to the depth of anesthesia; when a supplemental dose (5-10 mg/kg) of pentobarbital was administered the previously observed elevation in renal sympathetic nerve activity was inhibited (21) .
Inactin (used in the current study) provides a stable plane of anesthesia for up to 9 hours (32) . To examine directly whether the type of anesthesia affected Y 1 -receptor-dependent vascular control, additional studies were performed in three male Sprague-Dawley rats using -chloralose (80 mg/kg) and urethan (500 mg/kg). In these additional animals BIBP3226 infusion resulted in a 1.9 ± 0.7 µl/min/mmHg increase in hindlimb vascular conductance, similar to the current findings. These data provide additional confidence that the anesthetic used here did not confound the validity of the current observations. A major assumption of the current study is that the activation of Y 1 -receptors was due to NPY released from sympathetic neuronal varicosities. Certainly, these neurons contain NPY (35) . However, other sources of NPY exist and these may have impacted on the current analysis. For example, in rats NPY is released from the adrenal medulla (23) as well as from aggregation of blood platelets (24) . However, the contribution of the adrenal medulla to circulating plasma NPY has been shown to be insignificant in sham operated rats (42) . Furthermore, adrenal demedullation fails to affect baseline NPY levels (23; 42) . Moreover, it has been shown that platelet derived NPY release is only observed in vivo during high stress and is negligible under basal conditions (42) .
In conclusion, these data provide evidence that Y 1 -receptor activation contributes to the maintenance of basal hindlimb vascular tone in the intact rat. In addition, the effect of baseline endogenous Y 1 -receptor activation on mean vascular conductance was similar to basal 1 -adrenoceptor effects. Finally, the obervations suggest that activation of Y 1 -and 1 -receptors leads to spatial differences in microvascular control in skeletal muscle. 
